Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AgfiledCriticalBayer Healthcare Ag
Priority to CU20070161ApriorityCriticalpatent/CU20070161A7/en
Publication of CU20070161A7publicationCriticalpatent/CU20070161A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a una forma de administración farmacéutica novedosa de inhibidores de PDE para administración intravenosa y a su aplicación para el tratamiento de enfermedades.The invention relates to a novel pharmaceutical administration form of PDE inhibitors for intravenous administration and its application for the treatment of diseases.
CU20070161A2007-07-092007-07-09
INTRAVENOUS FORMULATIONS OF PDE INHIBITORS 5
CU20070161A7
(en)
DERIVATIVES OF QUINOLINA 057; A PROCESS FOR PREPARATION; A PHARMACEUTICAL COMPOSITION; THE PREPARATION OF THIS AND THE USE OF THE COMPOUND TO PREPARE A MEDICINAL PRODUCT
DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
ANILINA-PYRIMIDINE DERIVATIVES SUBSTITUTED WITH SULFOXIMINE AS INHIBITORS OF CYCLINE-DEPENDENT KINASES (CDK) PRODUCTION AND USE OF THE SAME AS MEDICINAL PRODUCTS